The effects of neuroleptics (haloperidol and chlorpromazine) on the pharmacokinetics of valproic acid in schizophrenic patients. 1984

T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka

The steady state trough concentrations (Cmin) and pharmacokinetics of valproic acid were investigated in schizophrenic patients during the treatment of valproic acid, 200 mg, twice daily and after the one dose of 400 mg, respectively, with and without haloperidol (6 to 10 mg/day, N = 6) or chlorpromazine (100 to 300 mg/day, N = 6). Four to 5 Cmin were monitored just before the morning valproic acid dose for 3 to 4 days preceding the kinetic study. The overall Cmin of valproic acid with chlorpromazine (33.2 +/- 1.7 micrograms/ml, N = 25) was significantly (p less than 0.01) greater than without (27.1 +/- 1.4 micrograms/ml, N = 25). The majority of the mean valproic acid concentrations observed after the 400-mg dose were significantly (p less than 0.05 to 0.01) greater during the chlorpromazine treatment as compared to those without the phenothiazine. The mean t1/2 was shortened from 15.4 +/- 1.4 to 13.5 +/- 1.2 hours (p less than 0.05) with a comparable increase in the clearance from 7.18 +/- 0.38 to 8.32 +/- 0.34 ml/hour/kg (p less than 0.01) after the discontinuation of chlorpromazine. All the patients revealed an increase in the valproic acid clearance after the chlorpromazine therapy was discontinued. When viewed overall, such a trend as found in the chlorpromazine group was not observed in the haloperidol group. The results suggest that chlorpromazine, but not haloperidol, inhibits the metabolism of valproic acid. However, the clinical significance of the interaction awaits future study.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004569 Electroencephalography Recording of electric currents developed in the brain by means of electrodes applied to the scalp, to the surface of the brain, or placed within the substance of the brain. EEG,Electroencephalogram,Electroencephalograms
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
July 1989, Biological psychiatry,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
September 1964, Current therapeutic research, clinical and experimental,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
October 1979, Psychopharmacology,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
June 1968, Current therapeutic research, clinical and experimental,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
January 1983, Clinical pharmacy,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
April 1993, Biological psychiatry,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
December 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
September 1992, Pharmacopsychiatry,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
August 1978, Naunyn-Schmiedeberg's archives of pharmacology,
T Ishizaki, and K Chiba, and M Saito, and K Kobayashi, and R Iizuka
January 1990, Schizophrenia bulletin,
Copied contents to your clipboard!